Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, and the United States. It offers in-vitro diagnostic reagents for clinical chemistry analyzers. The company's products include the gentian calprotectin immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Cystatin C, a superior GFR marker for the diagnosis and therapeutic control of renal function; NT-proBNP Immunoassay for diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure; and Canine c-reactive protein (CRP) immunoassay, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine CRP in dog plasma and serum. It also provides turbidimetric SARS-CoV-2 total antibody immunoassay, a quantitative antibody test for detecting antibodies targeting the S1-subunit. Gentian Diagnostics ASA was incorporated in 2001 and is headquartered in Moss, Norway.
Stock data | 2024 | Change |
---|---|---|
Price | $4.47 | N/A |
Market Cap | $68.91M | N/A |
Shares Outstanding | 15.42M | N/A |
Employees | 55.00 | N/A |